Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Liver fibrosis. Displaying page 6 of 20.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2010-018523-26 Sponsor Protocol Number: AOBSMI2ENT001-010 Start Date*: 2010-03-17
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Immediate versus delayed treatment with Entecavir in patients with active chronic hepatitis B (CHB): impact on liver fibrosis.
    Medical condition: Patients with chronic HBV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001239-30 Sponsor Protocol Number: CIR976101 Start Date*: 2012-05-22
    Sponsor Name:Foundation for Liver Research
    Full Title: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY.
    Medical condition: Liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001363-37 Sponsor Protocol Number: RBHP_2016_ABERGEL Start Date*: 2016-11-18
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-seve...
    Medical condition: viral hepatitis C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004754-15 Sponsor Protocol Number: 3152-201-002 Start Date*: 2017-06-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024527-25 Sponsor Protocol Number: CRAD001H2307 Start Date*: 2013-07-23
    Sponsor Name:Novartis Farma SpA
    Full Title: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living ...
    Medical condition: Adults with end stage liver disease patients requiring a liver transplant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002496-10 Sponsor Protocol Number: GS-US-402-1852 Start Date*: 2017-02-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Nonalcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003107-29 Sponsor Protocol Number: N°005 Start Date*: 2015-08-07
    Sponsor Name:GALMED Pharmaceuticals LTD.
    Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).
    Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000474-11 Sponsor Protocol Number: 747-304 Start Date*: 2018-12-07
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatoh...
    Medical condition: Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000440-10 Sponsor Protocol Number: CADPT02A12001 Start Date*: 2020-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and com...
    Medical condition: non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003013-14 Sponsor Protocol Number: EFC10144 Start Date*: 2008-02-01
    Sponsor Name:sanofi-aventis recherche & development
    Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)
    Medical condition: Diabetic patients with Non-Alcoholic Steato-Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002046-71 Sponsor Protocol Number: CLIK066X2204 Start Date*: 2017-10-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH)
    Medical condition: obese patients with non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003012-61 Sponsor Protocol Number: EFC10143 Start Date*: 2008-02-01
    Sponsor Name:sanofi recherche & developpement
    Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)
    Medical condition: Non diabetic patients with Non-Alcoholic Steato-Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) HU (Prematurely Ended) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005523-27 Sponsor Protocol Number: CIRROXABAN Start Date*: 2015-07-30
    Sponsor Name:INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
    Full Title: Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis
    Medical condition: Liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002473-61 Sponsor Protocol Number: GS-US-321-0102 Start Date*: 2013-05-08
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects wi...
    Medical condition: Primary Sclerosing Cholangitis (PSC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005012-42 Sponsor Protocol Number: 747-302 Start Date*: 2016-01-05
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004557-14 Sponsor Protocol Number: NA Start Date*: 2015-02-09
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King’s College Hospital NHS Foundation Trust
    Full Title: Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
    Medical condition: Immunosuppression withdrawal in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001428-33 Sponsor Protocol Number: PLN-74809-PSC-203 Start Date*: 2020-11-05
    Sponsor Name:Pliant Therapeutics, Inc
    Full Title: A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis ...
    Medical condition: Primary sclerosing cholangitis (PSC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) BE (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004325-91 Sponsor Protocol Number: CRAD001HIT34 Start Date*: 2014-01-25
    Sponsor Name:NOVARTIS FARMA S.p.A
    Full Title: Multicenter, prospective, open-label, controlled, randomized, parallel groups study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppr...
    Medical condition: liver transplant
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004515-56 Sponsor Protocol Number: hepatology_MT_2007-08 Start Date*: 2008-04-28
    Sponsor Name:Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG
    Full Title: Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016761-29 Sponsor Protocol Number: HE2013 Start Date*: 2010-05-14
    Sponsor Name:University of Birmingham
    Full Title: A 48-WEEK PHASE II, RANDOMISED, DOUBLE BLINDED PLACEBO CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE TRIAL ON LIRAGLUTIDE’S SAFETY, EFFICACY AND ACTION ON LIVER HISTOLOGY AND METABOLISM IN OVERWEIGHT PA...
    Medical condition: Non-alcoholic steatohepatits (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.0 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 12:09:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA